Table 1 Baseline characteristics of enrolled RA patients
Variable | Total RA patients (N = 54) |
|---|---|
Age | 60.4 ± 10.5 |
Gender (male, %) | 13 (24.1%) |
BMI | 23.0 [21.5; 26.1] |
Systolic blood pressure (mmHg) | 128.8 ± 14.9 |
Diastolic blood pressure (mmHg) | 74.7 ± 10.0 |
Disease duration (years) | 7.3 ± 7.6 |
Hypertension | 15 (27.8%) |
Diabetes Mellitus | 5 (9.3%) |
Dyslipidemia | 18 (33.3%) |
Smoking status | |
Never smoker | 40 (74.1%) |
Ex-smoker | 4 (7.4%) |
Current smoker | 10 (18.5%) |
Premature angina or heart attack in a 1st degree relative | 2 (3.7%) |
RF positivity | 44 (81.5%) |
Anti-CCP positivity | 42/53 (79.2%) |
ESR (mm/h) | 18.5 [4.0; 32.0] |
hsCRP (mg/dL) | 0.1 [0.0; 0.3] |
Total cholesterol (mg/dL) | 188.3 ± 41.2 |
HDL-C (mg/dL) | 64.3 ± 19.0 |
LDL-C (mg/dL) | 100.1 ± 36.1 |
Triglyceride (mg/dL) | 106.0 [69.0; 154.0] |
Atherogenic index of plasma | −0.1 ± 0.3 |
Biologics | 16 (29.6%) |
TNF-α inhibitor | 4 (7.4%) |
JAK inhibitor | 6 (11.1%) |
Tocilizumab | 5 (9.3%) |
Abatacept | 1 (1.9%) |
Methotrexate | 40 (74.1%) |
Sulfasalazine | 18 (33.3%) |
Hydroxychloroquine | 21 (38.9%) |
Tacrolimus | 5 (9.3%) |
Leflunomide | 5 (9.3%) |
Oral glucocorticoid | 38 (70.4%) |
DAS28-ESR | 2.4 [1.4; 3.2] |
DAS28-CRP | 1.4 [1.1; 2.2] |
CDAI | 3.0 [2.0; 6.0] |
mHAQ | 0.0 [0.0; 0.1] |
CAC score | 0.0 [0.0; 16.7] |
Framingham risk score | 3.2 [1.2; 9.0] |
SCORE for low risk region | 1.5 [0.0; 3.0] |
SCORE for high risk region | 3.0 [1.5; 4.5] |
ASCVD risk estimator plus | 8.2 [3.4; 19.4] |
QRISK3 | 13.4 [5.9; 22.1] |
ERS-RA | 7.7 [3.8; 14.4] |
Reynolds Risk Score | 2.0 [1.0; 4.0] |